Global Solid Tumor Therapeutics Market - Growth, Trends and Forecast 2017 - 2022

  • ID: 4388594
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global Soild tumor therapeutics market accounted for a market value of USD XX million in 2015 and is expected to reach USD XX million by 2016. The market is expected to reach USD XX million by 2021, growing at a CAGR of XX% during the forecast period of 2016 to 2021. According to WHO, around 8 million people died with various forms of cancer around the world in 2012, the number of new cases is expected to rise by about 70% over the next 2 decades. North America and Europe holds the top two positions in solid tumor therapeutics market due to high incidence rate.

Soild tumor therapeutics are pharmaceuticals that specifically treat various cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer and others. Solid tumors are an abnormal mass of tissue that usually does not contain cysts or liquid areas. Market analysis in this report provides insight on major players in solid tumor therapeutics that are operating in the market. It helps the new players to understand the business models and identify the product lines of the specific companies to establish in solid tumor therapeutics market. The increasing investment in R&D of therapeutics, increasing expenditure in healthcare, unmet need for efficacious drug and growing competition for new drugs are key factors propelling the growth of the market. However, increasing cost of R&D, drugs going off patent, increasing generic products, and high cost of therapy are turning out to be restraints for the market.

The solid tumor therapeutics market have been segmented based on the type of cancer, drugs and geography. The solid tumor therapeutics have been segmented based on the type of cancer and it is classified into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer and others. The segment of drugs are as follows: Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Doxorubicin, Bevacizumab (Avastin), Erlotinib (Tarceva), Sunitinib (Sutent), Everolimus (Afinitor), Docetaxel (Taxotere), Abiraterone acetate (Zytiga), Cabazitaxel (Jevtana) and others

This report have been geographically segmented into North America, Europe, Asia-Pacific, Middle East & Africa and South America. The North American region have been further segmented into USA, Canada and Mexico. The Europe region have been sub-divided into Germany, France, UK, Spain, Italy, Scandinavia, Benelux and Rest of Europe. The Asia-Pacific market have been segmented into Japan, China, India, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East & African market have been subdivided into GCC countries, South Africa and rest of Middle East and Africa. The South American market have been segmented into Brazil, Argentina and rest of South America. North America accounts for the largest market share.

In the current scenario with increase of biosimilars, it shows growth trends in the solid tumor therapeutics market, biosimilars accounted for approximately 60% of the market in 2015. The key players in the market are Kyowa Hakko Kirin Co., Ltd., GlaxoSmithKline plc, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Baxter International, Inc., Boehringer Ingelheim GmbH, Biogen Idec, Inc., Amgen, Inc., Abbott Laboratories, Inc., AstraZeneca plc, Sanofi and others.

Key Deliverables:

Market analysis for the Global solid tumor therapeutics market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market shares

Identification and analysis of the macro and micro factors that affect the Global solid tumor therapeutics market

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. INTRODUCTION
1.1 Study deliveratives
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and forecasr period years
1.6 General Study Assumptions
2. RESEARCH METHODOLOGY
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW AND INDUSTRY TRENDS
5.1 Current market scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of suppliers
5.2.2 Bargaining power of buyers
5.2.3 Degree of competition
5.2.4 Threat of substitution
5.2.5 Threat of new entrants
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 Market Drivers
6.1.1 Increasing prevalence of cancer
6.1.2 Increase in demand for POC testing
6.1.3 Demand for personalized drugs
6.1.4 Increase in molecular testing
6.1.5 Changes in healthcare system
6.2 Market Restraints
6.2.1 Regulatory issues
6.2.2 Shortage of accurate cancer testing kits
6.3 Market opportunities
6.3.1 Emergence of biosimilars
6.4 Key Challenges
6.4.1 Lack of skilled technicians
7. GLOBAL SOLID TUMOUR THERAPEUTICS MARKET -SEGMENTATION
7.1 BASED ON TYPE OF CANCER
7.1.1 BREAST CANCER
7.1.2 LUNG CANCER
7.1.3 COLORECTAL CANCER
7.1.4 PROSTATE CANCER
7.1.5 CERVICAL CANCER
7.1.6 OTHERS
7.2 BASED ON TYPE OF DRUGS
7.2.1 CARBOPLATIN
7.2.2 CISPLATIN
7.2.3 GEMCITABINE
7.2.4 PACLITAXEL
7.2.5 DOXORUBICIN
7.2.6 BEVACIZUMAB(AVASTIN)
7.2.7 ERLOTINIB(TARCEVA)
7.2.8 SUNITINIB(SUTENT)
7.2.9 EVEROLIMUS(AFINITOR)
7.2.10 DOCETAXEL(TAXOTERE)
7.2.11 ABIRATERONE ACETATE(ZYTIGA)
7.2.12 CABAZITAXEL(JEVTANA)
7.2.13 OTHERS
8. Global Psoriasis disease drug market by Geography - Regional shares and forecast
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 AstraZeneca plc
10.2 Sanofi
10.3 F. Hoffmann-La Roche Ltd.
10.4 Biogen Idec, Inc.
10.5 Boehringer Ingelheim GmbH
10.6 GlaxoSmithKline plc
10.7 Bristol-Myers Squibb Company
10.8 Johnson & Johnson
10.9 Eli Lilly and Company
10.10 Kyowa Hakko Kirin Co., Ltd.
10.11 Amgen, Inc.
10.12 Baxter International, Inc.
10.13 Abbott Laboratories, Inc
10.14 Others
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll